Angiogenesis, the growth of new vessels from preexisting vasculature, is a critical step in tumor
progression [1]. The tyrosine kinase Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is
a crucial mediator in angiogenesis since the VEGF, excreted by the tumor cells, binds to it
activating several signaling pathways involved in cell survival and proliferation [2]. Recently
thienopyridine derivatives showed to be promising inhibitors of the tyrosine kinase domain of
VEGFR2 [3,4]. In this work new N-[3-(thieno[3,2-b]pyridine-7-ylthio)phenyl]benzamides were
prepared as potential VEGFR2 inhibitors suggested by rational design, as presented below.FCT -Portugal for financial support through the NMR Portuguese network (Bruker 400 Avance 111-Univ
Minho). FCT and FEDER -COMPETE-QREN-EU for financial support through the research unities PEstC/
QUI/UI686/2011, PEst-OE/AGR/UI0690/2011, the research project PTDC/QUI-QUI/111 060/2009 and the
post-Doctoral grant A.B.(SFRH/BPD/36753/2007) also financed by POPH and FSE
